Oncology Net Income Applicable To Common Shares from 2010 to 2026
| TOI Stock | USD 2.45 0.14 5.41% |
Net Income Applicable To Common Shares | First Reported 2010-12-31 | Previous Quarter 61.2 K | Current Value 64.3 K | Quarterly Volatility 3.6 M |
Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 4.3 M or Interest Expense of 9.1 M, as well as many indicators such as Price To Sales Ratio of 0.0644, Dividend Yield of 0.0105 or PTB Ratio of 9.87. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
Oncology | Net Income Applicable To Common Shares | Build AI portfolio with Oncology Stock |
The Net Income Applicable To Common Shares trend for Oncology Institute offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Oncology Institute is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Oncology Institute's Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Oncology Institute over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Oncology Institute's Net Income Applicable To Common Shares historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Oncology Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (2,605,631) | |
| Geometric Mean | 930,797 | |
| Coefficient Of Variation | (139.43) | |
| Mean Deviation | 2,219,487 | |
| Median | (1,993,628) | |
| Standard Deviation | 3,633,161 | |
| Sample Variance | 13.2T | |
| Range | 14.4M | |
| R-Value | 0.05 | |
| Mean Square Error | 14T | |
| R-Squared | 0 | |
| Significance | 0.83 | |
| Slope | 39,337 | |
| Total Sum of Squares | 211.2T |
Oncology Net Income Applicable To Common Shares History
About Oncology Institute Financial Statements
Investors use fundamental indicators, such as Oncology Institute's Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Oncology Institute's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 61.2 K | 64.3 K |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Oncology Institute Correlation against competitors. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is there potential for Health Care Equipment & Supplies market expansion? Will Oncology introduce new products? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.67) | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets | Return On Equity |
Investors evaluate Oncology Institute using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Oncology Institute's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Oncology Institute's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Oncology Institute's market price signifies the transaction level at which participants voluntarily complete trades.